These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
42. Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA. Morabito F; Gentile M; Ciolli S; Petrucci MT; Galimberti S; Mele G; Casulli AF; Mannina D; Piro E; Pinotti G; Palmieri S; Catalano L; Callea V; Offidani M; Musto P; Bringhen S; Baldini L; Tosi P; Di Raimondo F; Boccadoro M; Palumbo A; Cavo M Eur J Haematol; 2010 Mar; 84(3):223-8. PubMed ID: 19930441 [TBL] [Abstract][Full Text] [Related]
43. Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study. Davis NB; Taber DA; Ansari RH; Ryan CW; George C; Vokes EE; Vogelzang NJ; Stadler WM J Clin Oncol; 2004 Jan; 22(1):115-9. PubMed ID: 14701773 [TBL] [Abstract][Full Text] [Related]
44. [Efficacy of bortezomib combined dexamethasone in 24 patients with multiple myeloma]. Li J; Zhao Y; Luo SK; Huang BH; Ding Y; Tong XZ; Wang HH; Zheng D; Su C; Peng AH Ai Zheng; 2008 Apr; 27(4):429-34. PubMed ID: 18423132 [TBL] [Abstract][Full Text] [Related]
45. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. Goy A; Younes A; McLaughlin P; Pro B; Romaguera JE; Hagemeister F; Fayad L; Dang NH; Samaniego F; Wang M; Broglio K; Samuels B; Gilles F; Sarris AH; Hart S; Trehu E; Schenkein D; Cabanillas F; Rodriguez AM J Clin Oncol; 2005 Feb; 23(4):667-75. PubMed ID: 15613697 [TBL] [Abstract][Full Text] [Related]
46. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. Richardson PG; Wolf J; Jakubowiak A; Zonder J; Lonial S; Irwin D; Densmore J; Krishnan A; Raje N; Bar M; Martin T; Schlossman R; Ghobrial IM; Munshi N; Laubach J; Allerton J; Hideshima T; Colson K; Poradosu E; Gardner L; Sportelli P; Anderson KC J Clin Oncol; 2011 Nov; 29(32):4243-9. PubMed ID: 21990396 [TBL] [Abstract][Full Text] [Related]
47. Bortezomib: new drug. A last resort in myeloma: modest efficacy, major risks. Prescrire Int; 2005 Jun; 14(77):94-8. PubMed ID: 15981389 [TBL] [Abstract][Full Text] [Related]
48. Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed-refractory multiple myeloma. Offidani M; Corvatta L; Polloni C; Gentili S; Mele A; Rizzi R; Catarini M; Caraffa P; Samori A; Blasi N; Ferranti M; Malerba L; Brunori M; Leoni P Ann Hematol; 2011 Dec; 90(12):1449-56. PubMed ID: 21437586 [TBL] [Abstract][Full Text] [Related]
49. Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. Chen CI; Kouroukis CT; White D; Voralia M; Stadtmauer E; Stewart AK; Wright JJ; Powers J; Walsh W; Eisenhauer E; J Clin Oncol; 2007 Apr; 25(12):1570-5. PubMed ID: 17353550 [TBL] [Abstract][Full Text] [Related]
50. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Ghobrial IM; Weller E; Vij R; Munshi NC; Banwait R; Bagshaw M; Schlossman R; Leduc R; Chuma S; Kunsman J; Laubach J; Jakubowiak AJ; Maiso P; Roccaro A; Armand P; Dollard A; Warren D; Harris B; Poon T; Sam A; Rodig S; Anderson KC; Richardson PG Lancet Oncol; 2011 Mar; 12(3):263-72. PubMed ID: 21345726 [TBL] [Abstract][Full Text] [Related]
51. Management of multiple myeloma with bortezomib: experts review the data and debate the issues. Dicato M; Boccadoro M; Cavenagh J; Harousseau JL; Ludwig H; San Miguel J; Sonneveld P Oncology; 2006; 70(6):474-82. PubMed ID: 17283449 [TBL] [Abstract][Full Text] [Related]
52. A phase II evaluation of bortezomib in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study. Aghajanian C; Blessing JA; Darcy KM; Reid G; DeGeest K; Rubin SC; Mannel RS; Rotmensch J; Schilder RJ; Riordan W; Gynecol Oncol; 2009 Nov; 115(2):215-20. PubMed ID: 19712963 [TBL] [Abstract][Full Text] [Related]
53. Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up. Berenson JR; Yang HH; Vescio RA; Nassir Y; Mapes R; Lee SP; Wilson J; Yellin O; Morrison B; Hilger J; Swift R Ann Hematol; 2008 Aug; 87(8):623-31. PubMed ID: 18463870 [TBL] [Abstract][Full Text] [Related]
54. Bortezomib with or without dexamethasone in relapsed multiple myeloma following allogeneic hematopoietic cell transplantation. Bruno B; Patriarca F; Sorasio R; Mattei D; Montefusco V; Peccatori J; Bonifazi F; Petrucci MT; Milone G; Guidi S; Giaccone L; Rotta M; Fanin R; Boccadoro M; Corradini P; Haematologica; 2006 Jun; 91(6):837-9. PubMed ID: 16769588 [TBL] [Abstract][Full Text] [Related]
55. Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma. Jagannath S; Barlogie B; Berenson JR; Siegel DS; Irwin D; Richardson PG; Niesvizky R; Alexanian R; Limentani SA; Alsina M; Esseltine DL; Anderson KC Br J Haematol; 2008 Nov; 143(4):537-40. PubMed ID: 18783399 [TBL] [Abstract][Full Text] [Related]
56. Optimizing the efficacy and safety of bortezomib in relapsed multiple myeloma. Richardson P; Jagannath S; Colson K Clin Adv Hematol Oncol; 2006 May; 4(5):1; discussion 8; suppl 13. PubMed ID: 16830422 [TBL] [Abstract][Full Text] [Related]
57. [Lung injury associated with bortezomib therapy in relapsed/refractory multiple myeloma in Japan: a questionnaire-based report from the "Lung Injury by Bortezomib" Joint Committee of the Japanese Society of Hematology and the Japanese Society of Clinical Hematology]. Gotoh A; Ohyashiki K; Oshimi K; Usui N; Hotta T; Dan K; Ikeda Y; ; Rinsho Ketsueki; 2006 Dec; 47(12):1521-7. PubMed ID: 17233470 [TBL] [Abstract][Full Text] [Related]
58. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma. San-Miguel JF; Richardson PG; Günther A; Sezer O; Siegel D; Bladé J; LeBlanc R; Sutherland H; Sopala M; Mishra KK; Mu S; Bourquelot PM; Victoria Mateos M; Anderson KC J Clin Oncol; 2013 Oct; 31(29):3696-703. PubMed ID: 24019544 [TBL] [Abstract][Full Text] [Related]
59. Bortezomib-induced cutaneous lesions in multiple myeloma patients: a case report. Rodríguez-Martín M; Sáez-Rodríguez M; García-Bustínduy M; Martín-Herrera A; Noda-Cabrera A Dermatol Online J; 2008 Nov; 14(11):14. PubMed ID: 19094852 [TBL] [Abstract][Full Text] [Related]
60. Recurrent capillary leak syndrome following bortezomib therapy in a patient with relapsed myeloma. Hsiao SC; Wang MC; Chang H; Pei SN Ann Pharmacother; 2010 Mar; 44(3):587-9. PubMed ID: 20150504 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]